How is Osimertinib reimbursed by medical insurance?

Osimertinib（Osimertinib）The original drug has been launched in China and has entered the scope of medical insurance. The reimbursement conditions are limited to epidermal growth factor receptor (EGFR) exon 19 deficiency. First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with deletions or exon 21 (L858R) substitution mutations, and who have had disease progression during or after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and have been tested to confirm the presence of EGFR Treatment of adult patients with T790M mutation-positive locally advanced or metastatic non-small cell lung cancer.

Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that binds to certain mutated forms of EGFR (T790M, L858R, and exon 19 deletions) that predominate in non-small cell lung cancer (NSCLC) tumors following first-line EGFR-TKIs treatment. As a third-generation tyrosine kinase inhibitor, osimertinib is specific for the gatekeeper T790M mutation, which increases ATP binding activity to EGFR and leads to poor prognosis in advanced disease.

OsimertinibThe name of the original drug on the domestic market is Osimertinib mesylate tablets, specificationsThe price of each box of 80mg*30 tablets is around RMB 5,000. The reimbursement ratios are different in different regions. The price after reimbursement may be different, and the price is relatively expensive. The original drug of Osimertinib has also been launched overseas, and there are also generics of Osimertinib produced in other countries. For example, the price of 80mg*30 tablets per box produced by Bangladesh Yaopin International is around RMB 850 (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of the generic Osimertinib and the original drug are basically the same.